ID   JAR
AC   CVCL_0360
SY   Jar; JAr; JaR
DR   BTO; BTO:0001585
DR   CLO; CLO_0007011
DR   EFO; EFO_0002211
DR   MCCL; MCC:0000254
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-144
DR   BCRC; 60491
DR   BioSample; SAMN01821568
DR   BioSample; SAMN01821637
DR   BioSample; SAMN03472717
DR   cancercelllines; CVCL_0360
DR   CCRID; 3101HUMTCHu156
DR   Cell_Model_Passport; SIDM01039
DR   ChEMBL-Cells; CHEMBL3307657
DR   ChEMBL-Targets; CHEMBL614587
DR   CLS; 300221
DR   Cosmic; 907175
DR   Cosmic; 2077193
DR   Cosmic-CLP; 907175
DR   DepMap; ACH-001529
DR   DSMZ; ACC-462
DR   DSMZCellDive; ACC-462
DR   EGA; EGAS00001000978
DR   GDSC; 907175
DR   GEO; GSM827264
DR   GEO; GSM1669947
DR   IARC_TP53; 21417
DR   IGRhCellID; JAR
DR   IZSLER; BS TCL 182
DR   KCLB; 30144
DR   LINCS_LDP; LCL-1491
DR   PharmacoDB; JAR_676_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0360
DR   PubChem_Cell_line; CVCL_0360
DR   TOKU-E; 2064
DR   Wikidata; Q54898511
RX   DOI=10.1007/0-306-46861-1_8;
RX   DOI=10.1007/BF02619074;
RX   PubMed=2720636;
RX   PubMed=2878840;
RX   PubMed=3518877;
RX   PubMed=4038916;
RX   PubMed=7153601;
RX   PubMed=7716126;
RX   PubMed=7819056;
RX   PubMed=7937597;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=24098444;
RX   PubMed=27397505;
RX   PubMed=28161053;
RX   PubMed=28534963;
RX   PubMed=28724925;
RX   PubMed=30894373;
RX   PubMed=33096371;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~20-30 hours (DSMZ=ACC-462).
CC   Karyotypic information: Near triploid karyotype (PubMed=33096371).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=30.11%; Native American=0.66%; East Asian, North=2.4%; East Asian, South=0%; South Asian=1.4%; European, North=42.28%; European, South=23.14% (PubMed=30894373).
CC   Caution: Established from the trophoblastic tumor of the placenta of a 24 year old woman, but the cell line is from the male fetus.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; KCLB
ST   Amelogenin: X,Y
ST   CSF1PO: 7,10
ST   D13S317: 11
ST   D16S539: 9,10
ST   D18S51: 13,17 (CLS)
ST   D18S51: 14,15 (DSMZ)
ST   D19S433: 12,13
ST   D21S11: 28,29 (DSMZ)
ST   D21S11: 30 (CLS)
ST   D2S1338: 20,21
ST   D3S1358: 14 (CLS)
ST   D3S1358: 14,16,17 (DSMZ)
ST   D3S1358: 16,17 (KCLB)
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 22
ST   Penta D: 9,11 (CLS)
ST   Penta D: 9,14 (DSMZ)
ST   Penta E: 10,12 (CLS)
ST   Penta E: 8,12 (DSMZ)
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C4646; Gestational choriocarcinoma
DI   ORDO; Orphanet_99926; Gestational choriocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Fetus
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   DOI=10.1007/0-306-46861-1_8;
RA   Ganapathy V., Prasad P.D., Leibach F.H.;
RT   "Choriocarcinoma.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.141-147; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1007/BF02619074;
RA   Pattillo R.A., Ruckert A.C.F., Hussa R.O., Bernstein R., Delfs E.;
RT   "The JAr cell line -- continuous human multihormone production and
RT   controls.";
RL   In Vitro 6:398-399(1971).
//
RX   PubMed=2720636; DOI=10.1016/0165-4608(89)90664-X;
RA   Surti U., Habibian R.;
RT   "Chromosomal rearrangement in choriocarcinoma cell lines.";
RL   Cancer Genet. Cytogenet. 38:229-240(1989).
//
RX   PubMed=2878840; DOI=10.1016/0020-7292(86)90088-3;
RA   Yamashita K., Nakamura T., Shimizu T., Katagiri M., Ikeda H.;
RT   "Expression of HLA class I and class II antigens in human
RT   choriocarcinoma cell lines.";
RL   Int. J. Gynecol. Obstet. 24:301-307(1986).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4038916; DOI=10.1016/0165-4608(85)90052-4;
RA   Sheppard D.M., Fisher R.A., Lawler S.D.;
RT   "Karyotypic analysis and chromosome polymorphisms in four
RT   choriocarcinoma cell lines.";
RL   Cancer Genet. Cytogenet. 16:251-258(1985).
//
RX   PubMed=7153601;
RA   Sasaki S., Katayama P.K., Roesler M., Pattillo R.A., Mattingly R.F.,
RA   Ohkawa K.;
RT   "Cytogenetic analysis of choriocarcinoma cell lines.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 34:2253-2256(1982).
//
RX   PubMed=7716126; DOI=10.1016/0143-4004(95)90079-9;
RA   Mitchell A.M., Yap A.S., Payne E.J., Manley S.W., Mortimer R.H.;
RT   "Characterization of cell polarity and epithelial junctions in the
RT   choriocarcinoma cell line, JAR.";
RL   Placenta 16:31-39(1995).
//
RX   PubMed=7819056; DOI=10.1038/bjc.1995.3;
RA   Yaginuma Y., Yamashita T., Takuma N., Katayama H., Ishikawa M.;
RT   "Analysis of the p53 gene in human choriocarcinoma cell lines.";
RL   Br. J. Cancer 71:9-12(1995).
//
RX   PubMed=7937597; DOI=10.1016/0143-4004(94)90008-6;
RA   Grummer R., Hohn H.-P., Mareel M.M., Denker H.-W.;
RT   "Adhesion and invasion of three human choriocarcinoma cell lines into
RT   human endometrium in a three-dimensional organ culture system.";
RL   Placenta 15:411-429(1994).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24098444; DOI=10.1371/journal.pone.0076205;
RA   Vuoristo S., Toivonen S., Weltner J., Mikkola M., Ustinov J.,
RA   Trokovic R., Palgi J., Lund R.J., Tuuri T., Otonkoski T.;
RT   "A novel feeder-free culture system for human pluripotent stem cell
RT   culture and induced pluripotent stem cell derivation.";
RL   PLoS ONE 8:E76205-E76205(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28161053; DOI=10.1016/j.placenta.2016.12.007;
RA   Abou-Kheir W., Barrak J., Hadadeh O., Daoud G.;
RT   "HTR-8/SVneo cell line contains a mixed population of cells.";
RL   Placenta 50:1-7(2017).
//
RX   PubMed=28534963; DOI=10.3892/or.2017.5661;
RA   Nishino K., Yamamoto E., Niimi K., Sekiya Y., Yamashita Y.,
RA   Kikkawa F.;
RT   "N-acetylglucosaminyltransferase IVa promotes invasion of
RT   choriocarcinoma.";
RL   Oncol. Rep. 38:440-448(2017).
//
RX   PubMed=28724925; DOI=10.1038/s41598-017-06364-z;
RA   Rothbauer M., Patel N., Gondola H., Siwetz M., Huppertz B., Ertl P.;
RT   "A comparative study of five physiological key parameters between four
RT   different human trophoblast-derived cell lines.";
RL   Sci. Rep. 7:5892-5892(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=33096371; DOI=10.1016/j.placenta.2020.10.011;
RA   Weber M., Weise A., Vasheghani F., Gohner C., Fitzgerald J.S.,
RA   Liehr T., Markert U.R.;
RT   "Cytogenomics of six human trophoblastic cell lines.";
RL   Placenta 103:72-75(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//